sociations with bronchopulmonary dysplasia (BPD) and survival without major neonatal morbidity. Methods: This was a population-based cohort study in 19 regions in 11 European countries conducted during 2011 and 2012. A total of 6,896 infants with data on PDA treatment were included. The differences in infant characteristics were studied across regions using a propensity score derived from perinatal risk factors for PDA treatment. The primary outcomes were a composite of BPD or death before 36 weeks postmenstrual age, or survival without major neonatal morbidity. Results: The proportion of PDA treatment varied from 10 to 39% beKeywords Neonatology · Epidemiology · Evidence-based medicine · Preterm infant outcome · Bronchopulmonary dysplasia · Neonatal surgery Abstract Background: Spontaneous closure of patent ductus arteriosus (PDA) occurs frequently in very preterm infants and despite the lack of evidence for treatment benefits, treatment for PDA is common in neonatal medicine. Objectives: The aim of this work was to study regional variations in PDA treatment in very preterm infants ( ≤ 31 weeks of gestation), its relation to differences in perinatal characteristics, and as- tween regions ( p < 0.001), and this difference could not be explained by differences in perinatal characteristics. The regions were categorized according to a low (<15%, n = 6), medium (15-25%, n = 9), or high (>25%, n = 4) proportion of PDA treatment. Infants treated for PDA, compared to those not treated, were at higher risk of BPD or death in all regions, with an overall propensity score adjusted risk ratio of 1.33 (95% confidence interval 1.18-1.51). Survival without major neonatal morbidity was not related to PDA treatment. Conclusions: PDA treatment varies largely across Europe without associated variations in perinatal characteristics or neonatal outcomes. This finding calls for more uniform guidance for PDA diagnosis and treatment in very preterm infants.
Introduction
Patent ductus arteriosus (PDA) is common in very preterm infants ( ≤ 31 gestational weeks) and is associated with systemic hypoperfusion that may increase the risk of intraventricular hemorrhage and necrotizing enterocolitis [1, 2] . A hemodynamically significant PDA may cause pulmonary congestion and increase the risk of bronchopulmonary dysplasia (BPD) [3] . Many clinicians therefore attempt pharmacological or surgical PDA closure in infants with a hemodynamically significant PDA.
In spite of extensive research including clinical trials, it has been difficult to provide evidence for improved outcomes after PDA treatment, partly because of the high spontaneous closure rate and the high incidence of open label treatment [4] [5] [6] [7] [8] . Other remaining questions regarding PDA treatment include the optimal timing of treatment [9, 10] and subsequent long-term outcome [11, 12] .
Conditions with large variations in management may benefit from increased standardization to improve care [13] . We hypothesized that PDA management belongs to this category and that there are significant differences in PDA treatment in very preterm infants between different European regions. To test our hypothesis, we studied variations in PDA treatment in a large European population-based cohort. Secondly, we investigated how differences in PDA treatment are associated with differences in perinatal characteristics between the regions. Finally, we assessed the association between PDA treatment and risk of BPD or death, or survival without major neonatal morbidity.
Methods
The Effective Perinatal Intensive Care in Europe (EPICE) Cohort Study was a population-based study of all births between 22+0 and 31+6 weeks of gestation in 19 regions across 11 European countries, conducted in 2011 and 2012 (www.epiceproject.eu; Appendix). Inclusions occurred over 12 months except in France (6 months). Infants who survived ≥ 24 h after birth were included in this study. Fifteen of the 247 neonatal units with >20% missing data on PDA treatment were excluded (431 infants from 5 regions in 4 countries). The final study sample included 6,896 infants ( Fig. 1 ). There were no significant differences in the gestational age (GA), birth weight, infant sex or mortality between infants included and those excluded ( n = 509).
Exposures PDA treatment was defined as any nonsteroidal anti-inflammatory (NSAID) treatment (ibuprofen or indomethacin) or surgery to close the PDA. Surgical treatment was categorized as either primary surgery or surgery following prior medical treatment. The postnatal age in days at the start of treatment was recorded.
Diagnosis of PDA was based on a clinical and/or echocardiographic assessment. We did not collect information on how PDA was diagnosed in the individual infant. Of the included units, 95.1%, caring for 6,768 (98.1%) of the included infants, could perform echocardiography on site.
Outcomes
The infant outcomes were: (i) a composite outcome of BPD (any oxygen treatment at 36 weeks postmenstrual age, PMA) or death before 36 weeks gestation, and (ii) survival without major neonatal morbidity (intraventricular hemorrhage grade ≥ 3, cystic periventricular leukomalacia, necrotizing enterocolitis requiring surgery or peritoneal drainage, or retinopathy of prematurity stage ≥ 3). Data were collected on each infant until death or hospital discharge (median PMA at discharge 37.4 weeks, interquartile range, IQR 36.0-39.1).
Covariates
The covariates selected for the analyses were: maternal age, multiple pregnancy, preeclampsia/eclampsia, spontaneous onset of labor, preterm premature rupture of membranes (pPROM), maternal infection as indication for delivery, administration of any antenatal corticosteroids, cesarean section, infant sex; GA at birth, small for GA (categorized as birth weight <3rd or between the 3rd and <10th percentiles for GA and sex using Hadlock references adapted to regional population values using the Gardosi model) [14, 15] , use of mechanical ventilation (started on the first day of life or total duration among survivors to ≥ 36 weeks PMA), and the number of septicemias confirmed by blood culture.
Ethical approval and informed parental consent (active or passive, depending on each participating country's national legislation) for data collection were obtained in each study region. EPICE regions were selected in part because of the existence of preexisting data collection systems for the routine monitoring of births which made it possible to collect data on all very preterm births. In the French regions, EPICE was carried out as part of the EPIPAGE 2 study and parents had to consent to all parts of data collection, leading to 6.4% of total births for which consent could not be obtained, including stillbirths and terminations of pregnancy. The European study was also approved by the French Advisory Committee on Use of Health Data in Medical Research (CCTIRS) and the French National Commission for Data Protection and Liberties (CNIL).
Statistical Analyses
Descriptive data are displayed as the median (IQR) for continuous data and percentage ( n , %) for categorical data. Differences between groups were tested using the Kruskal-Wallis test for continuous data, and χ 2 test for proportions. Associations between covariates and risk of PDA treatment were analyzed in mixed-effects generalized linear regression models adjusted for GA and with the neonatal unit as the random effect variable and reported as risk ratios (RR) with 95% confidence intervals (CI).
Differences in perinatal characteristics between the regions were explored by calculating a propensity score for PDA treatment for each subject, i.e. a single index variable summarizing the maternal and perinatal characteristics known or hypothesized to be either related to the exposure (PDA treatment) or the outcomes. The propensity score was calculated by fitting a logit model using the pscore command in STATA 13.1 including the covariates in online supplementary Table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000454798). The adequacy of the model was checked by evaluating the balance of the covariates across treatment groups.
Clustering of data was handled using a mixed-effects generalized linear regression model (as described above) to analyze the association between PDA treatment and the composite outcome of BPD or death, and between PDA treatment and survival without major neonatal morbidity. In supplementary analyses, clustering on mothers (for multiples) was evaluated by adding maternal identity as a second random effect level in the mixed-effects regression. Results from these regression analyses are reported as the propensity score aRR with 95% CI. In supplementary analyses of the association between PDA treatment and BPD in survivors, the results were further adjusted for the total duration of mechanical ventilation and number of confirmed septicemias. All data were analyzed in STATA 13.1 (www.stata.com).
Results
The study sample consisted of 6,896 infants (54% male) with a mean (SD) GA of 29.1 (2.2) weeks and a mean birth weight of 1,223 (384) g. Of these, 1,968 (28.5%) were born at <28 weeks and 4,928 (71.5%) between 28 and 31 weeks of gestation. The total incidence of any PDA treatment was 20% for the whole cohort; 44% for infants <28 weeks and 9.8% for infants born at 28-31 weeks of gestation. 
Pregnancy and Neonatal Factors Associated with PDA Treatment
The cohort characteristics by type of PDA treatment are presented in Table 1 . GA was strongly associated with PDA treatment. At 23 weeks of gestation, 60% of the infants received PDA treatment compared with 3.5% at 31 weeks ( p < 0.001; online suppl. Fig. 1 ). After adjustment for GA, the cohort characteristics associated with a higher risk for PDA treatment were multiple pregnancy, preeclampsia/eclampsia, cesarean delivery, small for GA, and neonatal septicemia. The cohort characteristics associated with a lower risk were pPROM, spontaneous onset of delivery, and infection as indication for delivery. Maternal age and use of antenatal corticosteroids were not associated with PDA treatment (online suppl. Table 2 ).
Regional Variations in PDA Treatment
Between the regions, the overall proportion of PDA treatment varied from 10 to 39% ( p < 0.001) ( Fig. 2 ) . In infants born before 28 weeks of gestation, the proportion of PDA treatment varied from 27 to 82% ( p < 0.001). The corresponding variation among infants born at 28-31 weeks was 2.9-26% ( p < 0.001). Regional variations in the type of PDA treatment are shown in online supplementary Figure 2 .
Based on the distribution of PDA treatment proportions, regions were categorized as low (<15%; n = 6), medium (15-25%; n = 9) or high (>25; n = 4) ( Fig. 2 ) . Regions with a high proportion of treated infants started pharmacological treatment earlier, and used PDA surgery more often than regions with low or medium proportions of Data are median (IQR), or proportions, %. n = 6,896 infants born at ≤31 weeks of gestation. SGA, small for gestational age; IVH, intraventricular hemorrhage; cPVL, cystic periventricular leukomalacia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity.
a Defined as a birth weight <3rd percentile for GA according to customized intrauterine growth curves. b Mechanical ventilation started on the first day of life. c n = 6,262 survivors to ≥36 weeks PMA having complete BPD data. d n = 6,390 surviving to ≥35 weeks PMA.
PDA treatment. In addition, high proportion regions used primary PDA surgery at a lower postnatal age than low-and medium-treatment regions. Regions with a high proportion of PDA treatment had the highest access to PDA surgery on site without transfer. Furthermore, medium proportion regions had higher access to PDA surgery on site than regions with a low proportion of treatment ( Table 2 ). There were no differences in postnatal age at the start of pharmacological between infants born before 28 or at 28-31 weeks of gestation (data not shown).
PDA Treatment and Perinatal Characteristics
The differences in perinatal characteristics, measured as propensity scores for PDA treatment, did not explain the variations in treatment observed between the regions. Regions with a low proportion of treatment had slightly higher propensity scores (median 0.45, IQR 0.34-0.56) for treatment among infants <28 weeks of gestation compared with regions with medium (median 0.42, IQR 0.31-0.55, p < 0.001) or high PDA treatment (median 0.42, IQR 0.35-0.48, p = 0.02). Among infants born at 28-31 weeks, Regions with a high proportion of PDA treatment had higher propensity scores than both low and medium regions (median 0.09, IQR 0.05-0.17, p < 0.001 for both comparisons) ( Fig. 3 ) .
PDA Treatment and Neonatal Outcome
Infants treated for PDA were at higher risk of BPD or death, with an overall propensity score aRR of 1.33 (95% CI 1.18-1.51). PDA treatment was associated with an increased aRR of BPD or death in all regions. The highest risks were observed among infants undergoing primary surgery, with an adjusted risk increase of 45% in regions with low proportions of PDA treatment, 79% in regions with medium proportions, and 176% in regions with high proportions of PDA treatment. These risks were accentuated when restricting the analyses to study BPD among survivors to 36 weeks PMA. Further adjustment for the duration of mechanical ventilation and number of confirmed septicemias slightly attenuated the association between PDA treatment and BPD, but a risk increase for BPD of 34, 67, and 154% remained in low, medium, and high-treatment regions, respectively (online suppl. Table 3). There was no association between PDA treatment and survival without major neonatal morbidity, regardless of the region ( Table 3 ) . Adjustment for clustering on mothers in multiples did not change the estimates.
Discussion
In this population-based study of very preterm infants across Europe, we found that PDA treatment varied 3-fold (<28 weeks) to 9-fold (28-31 weeks) between different regions. This regional variation was not explained by differences in perinatal characteristics. Our data confirm previous observations [16, 17] that GA is the most important predictor for PDA treatment, with a sharp decrease in PDA treatment from 23 to 31 weeks of gestation. The risk of BPD or death in infants treated for PDA was increased compared with untreated infants, and the association between PDA treatment and BPD was further strengthened when restricting the analyses to survivors to ≥ 36 weeks of gestation. Finally, PDA treatment was not associated with survival without major neonatal morbidity.
The incidence of any PDA treatment in EPICE was similar to that in other population-based European studies [16, 18, 19] , and slightly lower than reported in Canada and Japan [20] . In the NICHD Neonatal Research Network in the USA, the proportion of infants <28 weeks with a PDA diagnosis varied from 26 to 78% between different centers in 2003-2007, with a 3-fold variation in the use of pharmacological treatment and a 4-fold difference in PDA surgery, but data permitting a more detailed understanding of variations were lacking [17] . In EPICE, we found that differences in perinatal characteristics be- tween the regions did not explain the variations in PDA treatment.
The evidence base for PDA treatment is weak and has been debated in the last decade [5, 21, 22] . The large regional variation in treatment in EPICE could be driven by different treatment guidelines (or their absence) and use of echocardiography may differ between centers. Furthermore, the definition of a hemodynamically significant PDA may vary [23] . Recent data show that early PDA screening is associated with higher rates of PDA treatment, but lower in-hospital mortality [24] . Nevertheless, the lack of an association between PDA treatment and improved neonatal outcome supports the questioning of liberal PDA treatment. It should also be noted that up to 26% of infants born at 28-31 weeks were treated for PDA in some regions, which cannot be considered evidencebased given the high spontaneous closure rate [7] .
Whereas PDA treatment was found to be associated with an increased risk of BPD or death, this study cannot provide evidence for an underlying explanation. The severity of respiratory distress syndrome may have determined both the risk of PDA treatment and of BPD. In addition, both PDA and BPD are linked to conditions of inflammation -before and after birth -such as pPROM and neonatal infections [25] .
The highest risk for BPD or death was seen after PDA surgery. This association may have suffered from confounding by indication. However, given earlier findings of a strong association between PDA surgery and BPD risk [3] and the large increases in risk for BPD or death associated with surgery in our study, we cannot exclude that the surgical procedure per se or other factors may contribute to this increased risk.
The age at PDA surgery following prior medical PDA treatment did not differ between low, medium or hightreatment regions. However, primary surgery was performed 2-3 weeks earlier in high compared to low-and medium-treatment regions. In high-treatment regions, the access to PDA surgery onsite was also higher. This could indicate that centers in high-treatment regions have adopted a more proactive, early surgical approach, while the other regions use primary surgery more restrictively.
High-treatment regions used earlier pharmacological PDA treatment than the other regions. In other studies, the timing of pharmacological PDA treatment after extremely preterm birth has not been associated with the risk of PDA surgery or death, and expectant PDA management has not been associated with increased risk of BPD [26] , although contradictive observations have been c Results from a generalized linear mixed model adjusted for propensity score for PDA treatment. The propensity score for PDA treatment, i.e. a single index variable summarizing the pretreatment perinatal characteristics, was estimated from the presence of preeclampsia/eclampsia, spontaneous onset of labor, pPROM, maternal infection as indication for delivery, antenatal corticosteroid treatment, mode of delivery, GA, birth weight, infant sex, small for GA, and use of mechanical ventilation on the first day of life. reported [27] . We hypothesize that early timing of treatment may be one of the underlying factors leading to a higher treatment incidence, since spontaneous closure may not occur until after an early treatment decision has been made. This hypothesis is supported by the fact that the infants born at 28-31 weeks of gestation were treated at the same postnatal age as infants born at <28 weeks of gestation.
The strengths of this cohort study include its population-based design, the standardized data collection, and the large number of infants, regions, and countries included. Detailed data on PDA treatment were available and we believe that our results are generalizable to most European neonatal intensive care settings.
The main limitation is the lack of echocardiographic PDA characteristics, which hinders us from determining the PDA incidence in the untreated group, and studying the hemodynamic significance of the PDA in infants receiving treatment. Although there may be differences in the incidence of hemodynamically significant PDA between the regions, we do not think that such potential differences could be the only explanation for a 4-fold difference in PDA treatment between the regions.
Furthermore, it is a limitation that we could not take the neonatal disease burden into account in our propensity score model for PDA treatment. To avoid confounding, it is essential that factors used to predict treatment occur before the treatment. Since we did not have the exact dates of diseases, such as sepsis, or start and stop date of each episode of mechanical ventilation, we could not use these factors in the propensity score. Although we could not disentangle the temporal relationships with PDA treatment, adjusting for the total duration of mechanical ventilation and number of confirmed septicemias in supplementary analyses did not change the association between PDA treatment and an increased risk of BPD. Possible residual confounding and confounding by indication are additional limitations. Finally, we did not register if paracetamol had been administered to the infants.
In conclusion, there is a 4-fold variation in PDA treatment rates between European regions that could not be explained by differences in the perinatal characteristics between the regions. Liberal treatment was not associated with a lower risk of BPD or death, nor was it associated with a higher chance of survival free of major neonatal morbidity. It is also notable that a large proportion of infants born at 28-31 weeks are treated for PDA, although the spontaneous closure rate is known to be high in this group. These findings support a call for uniform guidance for the management of PDA in very preterm infants.
